SERB's €115M Deal to Unlock Kidney Transplants for Toughest Cases

BRUSSELS, BELGIUM – May 19, 2026 – In a move poised to reshape the landscape of organ transplantation, SERB Pharmaceuticals today announced a landmark €115 million agreement to acquire the European and MENA rights for Idefirix® (imlifidase), a groundbreaking drug developed by Hansa Biopharma. The deal provides a new pathway to life for thousands of patients who, until now, faced an almost insurmountable barrier to receiving a life-saving kidney transplant.

Idefirix® is a first-in-class treatment designed to help a specific, highly challenged group of patients. Each year, about 70,000 people in Europe with end-stage renal disease wait for a kidney transplant. Among them, an estimated 10-15% are deemed “highly sensitized,” meaning their immune systems are primed to attack a donor organ. For this group, finding a compatible kidney is exceptionally difficult, often leading to years on dialysis with diminishing hope. Idefirix® works by rapidly neutralizing the antibodies that cause this hyper-reactivity, creating a crucial window for a successful transplant.

“SERB is committed to expanding access to transplantation for highly sensitised patients who currently have very limited alternatives,” stated Jeremie Urbain, Chairman of SERB Pharmaceuticals, in the official announcement. “SERB is designed to address rare and urgent conditions, and will leverage its deep expertise, proven commercial execution and established platform across Europe and MENA to expand the reach and clinical impact of Idefirix®.”

A Strategic Play in Rare Diseases

For SERB Pharmaceuticals, the acquisition is far more than a single product deal; it is a calculated move that reinforces its identity as a major player in the high-stakes world of rare and urgent diseases. The company has methodically built a global presence through a “buy-and-build” strategy, completing 16 acquisitions over the last 12 years to assemble a robust portfolio of critical care medicines.

This strategy has seen SERB expand from its European roots into a global force with a significant US commercial presence, established through its 2021 acquisition of BTG Specialty Pharmaceuticals. The addition of Idefirix® aligns perfectly with a portfolio that includes antidotes, emergency medicines, and treatments for rare conditions where timing and efficacy are paramount. It follows other significant investments, such as the acquisition of Y-mAbs Therapeutics in 2025, which strengthened its rare disease pipeline in pediatric oncology.

The acquisition taps into the lucrative and growing rare disease market, which was valued at over $200 billion in 2023 and is projected to grow substantially. With over 95% of rare diseases still lacking an approved therapy, assets like Idefirix®—which address a clear, high-unmet need—are exceptionally valuable. The drug’s conditional approval in Europe and the UK already demonstrates a clear regulatory path, making it a prized asset for a company focused on commercial execution.

Unlocking a Bottleneck in Transplantation

The scientific challenge Idefirix® overcomes is profound. Highly sensitized patients develop high levels of antibodies against human leukocyte antigens (HLA), the proteins that mark cells as “self.” These antibodies, often a result of previous pregnancies, blood transfusions, or prior transplants, create a positive crossmatch with most potential donor kidneys, meaning the recipient's body would immediately reject the organ.

Traditional desensitization methods, such as plasmapheresis (filtering the blood) and intravenous immunoglobulin (IVIg), are often slow, costly, and not universally effective. Idefirix®, an enzyme derived from Streptococcus pyogenes, offers a more direct and rapid solution. It acts like a molecular scalpel, specifically cleaving IgG antibodies—the primary culprits in rejection—within hours of administration. This effectively disarms the patient's immediate immune response, allowing a transplant from a previously incompatible deceased donor to proceed.

For the medical community, this represents a significant breakthrough. Transplant surgeons and nephrologists have long grappled with the clinical and ethical dilemma of highly sensitized patients languishing on waitlists. Idefirix® provides a tangible tool to make transplantation a reality for this underserved population, potentially improving the overall efficiency and fairness of organ allocation systems.

A Transatlantic Strategy: A Win-Win for SERB and Hansa?

The €115 million deal structure—comprising a €110 million upfront payment and a €5 million milestone payment—highlights the value both companies see in the agreement. For SERB, it secures a high-impact, commercially ready asset for its core European and MENA territories. The company will take the reins on commercialization and future clinical obligations, including a long-term post-approval efficacy study (PAES) and an ongoing pediatric study.

For Hansa Biopharma, the deal is a strategic masterstroke. While it cedes control in Europe, the Swedish biopharma company gains a substantial non-dilutive cash infusion. Hansa has explicitly stated this capital will be used to fund an “optimized US launch” and propel the company toward profitability. This pivot to the vast US market, where an estimated 10,000-20,000 patients on the kidney transplant waitlist are highly sensitized, is a logical next step.

All eyes are now on the U.S. Food and Drug Administration (FDA), which accepted Hansa’s Biologics License Application (BLA) for the drug in February 2026. A Prescription Drug User Fee Act (PDUFA) action date is set for December 19, 2026. A favorable decision would open a market potentially larger than Europe and validate Hansa’s focused strategy. Meanwhile, the divestment allows Hansa to continue funding its broader pipeline, which explores the use of its IgG-cleaving enzyme technology in other autoimmune diseases and transplant settings.

Navigating the Path to Patients

Before SERB can fully leverage its new asset, the acquisition must clear customary regulatory hurdles, including foreign direct investment (FDI) approval, which is expected within the next 60 days. Following that, SERB and Hansa will collaborate on the submission for full approval from the European Medicines Agency (EMA), a process contingent on forthcoming data from the PAES study.

As the deal moves toward completion, it represents more than a financial transaction. For the thousands of highly sensitized patients on dialysis, it represents a renewed chance at a life free from the machine. As SERB integrates Idefirix® into its portfolio, the focus will shift from corporate strategy to the complex logistics of delivering this specialized treatment to hospitals and transplant centers across dozens of countries, turning a breakthrough therapy into a tangible reality for those who need it most.